Healthcare
Nicox Announces NCX 470 NDA in China Accepted for Review
Press Release Nicox Announces NCX 470 NDA in China Accepted for Review Acceptance of the NCX 470 dossier initiates the review processRegulatory decision expected within 12-18 months from the August submissionQ&A on Ocumension available on Nicox’s website September 11, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has
About this update from Nicox Sa
1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA). Attachment